Clinical evidence for the use of aspirin in the treatment of cancer

ecancermedicalscience

Volumn 7, Issue 1, 2013, Pages

  Langley, Ruth E ^a,b  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b UK   (United Kingdom)

Author keywords

Aspirin; Cancer; Mechanisms; Toxicity; Treatment

Indexed keywords

ACETYLSALICYLIC ACID;

ARTICLE; CANCER MORTALITY; CANCER PREVENTION; CANCER THERAPY; CLINICAL TRIAL; DRUG MECHANISM; DRUG MEGADOSE; GASTROINTESTINAL HEMORRHAGE; HUMAN; LOW DRUG DOSE; OVERALL SURVIVAL;

EID: 84876404642     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2013.297     Document Type: Article

References (42)

1. Gasic GJ, Gasic TB and Stewart CC (1968) Antimetastatic effects associated with platelet reduction Proc Natl Acad Sci USA 61(1) 46-52 DOI: 10.1073/pnas.61.1.46 PMID: 5246932
2. Gasic GJ, Gasic TB and Murphy S (1972) Anti-metastatic effect of aspirin Lancet 2(7783) 932-3 DOI: 10.1016/S0140-6736(72)92581-0 PMID: 4116642
3. Kune GA, Kune S and Watson LF (1988) Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study Cancer Res 48(15) 4399-404 PMID: 3390835
4. Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE and Hennekens CH (1998) Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study Ann Intern Med 128(9) 713-20 PMID: 9556464
5. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH and Buring JE (2005) Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomised controlled trial JAMA 294(1) 47-55 DOI: 10.1001/ jama.294.1.47 PMID: 15998890
6. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA and Baron JA (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352(11) 1092-102 DOI: 10.1056/NEJMoa050493 PMID: 15713943
7. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW and Verburg KM (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery N Engl J Med 352(11) 1081-91 DOI: 10.1056/NEJMoa050330 PMID: 15713945
8. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E and Bertagnolli M (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention N Engl J Med 352(11) 1071-80. DOI: 10.1056/NEJMoa050405 PMID: 15713944
9. Flossmann E and Rothwell PM (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies Lancet 369(9573) 1603-13 DOI: 10.1016/S0140-6736(07)60747-8 PMID: 17499602
10. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP and Meade TW (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials Lancet 376(9754) 1741-50 DOI: 10.1016/S0140- 6736(10)61543-7 PMID: 20970847
11. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP and Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials Lancet 377(9759) 31-41 DOI: 10.1016/S0140- 6736(10)62110-1
12. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JF, Wilson M, Mehta Z and Meade TW (2012) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials Lancet 379(9826) 1602-12 DOI: 10.1016/S0140-6736(11)61720-0 PMID: 22440946
13. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW and Mehta Z (2012) Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials Lancet 379(9826) 1591-601 DOI: 10.1016/S0140-6736(12)60209-8 PMID: 22440947
14. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard ML, Dunlop MG, Ho JW, Hodgson SV, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar R, Side L, Scott RJ, Thomas HJ, Vasen HF, Barker G, Crawford G, Elliott F, Movahedi M, Pylvanainen K, Wijnen JT, Fodde R, Lynch HT, Mathers JC and Bishop DT (2012) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial Lancet 378(9809) 2081-7 DOI: 10.1016/S0140-6736(11)61049-0
15. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D and Hankinson SE (2010) Aspirin intake and survival after breast cancer J Clin Oncol 28(9) 1467-72 DOI: 10.1200/JCO.2009.22.7918 PMID: 20159825 PMCID: 2849768
16. Chan AT, Ogino S and Fuchs CS (2009) Aspirin use and survival after diagnosis of colorectal cancer JAMA 302(6) 649-58 DOI: 10.1001/jama.2009.1112 PMID: 19671906
17. Bastiaannet E, Sampieri K, Dekkers OM, de Craen AJ, van Herk-Sukel MP, Lemmens V, van den Broek CB, Coebergh JW, Herings RM, van de Velde CJ, Fodde R and Liefers GJ (2012) Use of Aspirin postdiagnosis improves survival for colon cancer patients Br J Cancer 106(9) 1564-70 DOI: 10.1038/bjc.2012.101 PMID: 22454078
18. McCowan C, Munro AJ, Donnan PT and Steele RJC (2012) Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality Eur J Cancer. 2013 Mar; 49(5):1049-57. doi: 10.1016/j.ejca.2012.10.024. PMID: 23182687 Epub 2012 Nov 19.
19. Zaorsky NG, Buyyounouski MK, Li T and Horwitz EM (2012) Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy Int J Radiat Oncol Biol Phys 84(1) e13-7 DOI: 10.1016/j.ijrobp.2012.02. 050
20. Choe KS, Correa D, Jani AB and Liauw SL (2010) The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy Cancer 116(7) 1820-26 DOI: 10.1002/cncr.24890 PMID: 20143436
21. Liu J-F, Jamieson GG, Wu T-C, Zhu G-J and Drew PA (2009) A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia Ann Surg Oncol 16(5) 1397-1402 DOI: 10.1245/s10434-009-0382-z PMID: 19241108
22. US Preventative Services Task Force Routine aspirin or non-steroidal anti-inflammatory drugs for the prevention of colorectal cancer: recommendation statement Ann Intern Med 146(5) 361-4 PMID: 17339621
23. Cook N (2012) Aspirin and cancer: Evidence from randomised trials NCRI Conference 2012 Liverpool http://www.ncri.org.uk/ ncriconference/2012abstracts/ mobile/abstracts/Para89.html
24. Bosetti C, Rosato V, Gallus S, Cuzick J and La Vecchia C (2012) Aspirin and cancer risk: a quantitative review to 2011 Ann Oncol 23(6) 1403-15 DOI: 10.1093/annonc/mds113 PMID: 22517822
25. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, Chaussade S and Baron JA (2009) Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomised trials J Natl Cancer Inst 101(4) 256-66 DOI: 10.1093/jnci/ djn485
26. Langley RE, Burdett S, Tierney JF, Cafferty F, Parmar MK and Venning G (2011) Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer 105(8) 1107-13 DOI: 10.1038/bjc.2011.289 PMID: 21847126 PMCID: 3208483
27. Reader J, Holt D and Fulton A (2011) Prostaglandin E2 EP receptors as therapeutic targets in breast cancer Cancer Metastasis Rev 30(3-4) 449-63 DOI: 10.1007/s10555-011-9303-2
28. Thun MJ, Jacobs EJ and Patrono C (2012) The role of aspirin in cancer prevention. Nat Rev Clin Oncol 9(5):259-67 DOI: 10.1038/ nrclinonc.2011.199 PMID: 22473097
29. Honn KV, Tang DG and Crissman JD (1992) Platelets and cancer metastasis: a causal relationship? Cancer Metastasis Rev 11(3-4) 325-51. DOI: 10.1007/BF01307186
30. Gupta GP and Massague J (2004) Platelets and metastasis revisited: a novel fatty link J Clin Invest 114(12) 1691-3 PMID: 15599391 PMCID: 535073
31. Labelle M, Begum S and Hynes RO (2011) Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal- like transition and promotes metastasis Cancer Cell 20(5) 576-90 DOI: 10.1016/j.ccr.2011.09.009 PMID: 22094253
32. Kopp E and Ghosh S (1994) Inhibition of NF-kappa B by sodium salicylate and aspirin Science 265(5174) 956-9 DOI: 10.1126/ science.8052854 PMID: 8052854
33. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK and Levin B (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis N Engl J Med 342(26) 1946-52 DOI: 10.1056/NEJM200006293422603 PMID: 10874062
34. Thun MJ, Henley SJ and Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues J Natl Cancer Inst 94(4) 252-66 DOI: 10.1093/jnci/94.4.252 PMID: 11854387
35. Koki AT and Masferrer JL (2002) Celecoxib: a specific COX-2 inhibitor with anticancer properties Cancer Control 9(2 Suppl) 28-35
36. Brown JR and DuBois RN (2005) COX-2: a molecular target for colorectal cancer prevention J Clin Oncol 23(12) 2840-55 DOI: 10.1200/JCO.2005.09.051 PMID: 15837998
37. Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A, Dunson DB, Rogan EG, Morham SG, Smart RC and Langenbach R (2002) Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis Cancer Res 62(12) 3395-401 PMID: 12067981
38. Langenbach R, Loftin CD, Lee C and Tiano H (1999) Cyclooxygenase- deficient mice. A summary of their characteristics and susceptibilities to inflammation and carcinogenesis Ann N Y Acad Sci 889 52-61 DOI: 10.1111/j.1749-6632.1999.tb08723.x
39. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SG, Smithies O and Langenbach R (2000) Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice Cancer Res 60(17) 4705-8 PMID: 10987272
40. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT and Ogino S (2012) Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival New Engl J Med 367(17) 1596-1606 DOI: 10.1056/NEJMoa1207756 PMID: 23094721
41. James ND, Sydes MR, Mason MD, Clarke NW, Anderson J, Dearnaley DP, Dwyer J, Jovic G, Ritchie AW, Russell JM, Sanders K, Thalmann GN, Bertelli G, Birtle AJ, O'Sullivan JM, Protheroe A, Sheehan D, Srihari N and Parmar MK (2012) Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial Lancet Oncol 13(5) 549-58 DOI: 10.1016/S1470-2045(12)70088-8 PMID: 22452894 PMCID: 3398767
42. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC and Zanchetti A (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373(9678) 1849-60 DOI: 10.1016/S0140-6736(09)60503-1 PMID: 19482214